Quarterly Activities/Appendix 4C Cash Flow Report

• Secured five HiRise® devices purchase orders, the highest Q1 sales to date
• Received FDA clearance for CT-based BMD technology
• Raised A$7.35 million through capital raising initiatives
• Achieved regulatory clearance for HiRise® in China, triggering a A$1.0 million payment
• Reduced annualized cash-related operating expenditure to approximately $15 million

Curvebeam AI Ltd announced its Q1 FY27 financial results, highlighting significant sales of five HiRise® devices, the highest for Q1 to date. The company also received FDA clearance for its CT-based BMD technology, expanding its market reach. Curvebeam AI successfully raised A$7.35 million through various capital initiatives, including a placement, SPP, and Shortfall Offer. Additionally, the company achieved regulatory clearance for HiRise® in China, triggering a A$1.0 million payment and setting the stage for future sales. Operating expenses were reduced, with annualized cash-related operating expenditure now at approximately $15 million.

Curvebeam AI Ltd remains confident in its global sales pipeline, with a focus on expanding its market presence in China and leveraging its regulatory approvals to drive future growth.